益比奥治疗NSCLC化疗致贫血的临床观察

Clinical observation of recombinant human EPO for the treatment of anaemina induced by chemotherapy of non-mall cell lung cancer

目的观察益比奥(rhEPO)对非小细胞肺癌(NSCLC)化疗所致贫血的疗效。方法58例NSCLC因化疗所致贫血患者随机分组,益比奥组30例应用rhEPO 150 U/kg皮下注射每周3次;复方阿胶浆组28例给予复方阿胶浆20 ml/次,3次/d。结论治疗4周后应用rhEPO组与复方阿胶浆组比较RBC、Hb、HCT值均上升(P<0.05)差异有显著性;有效率治疗组74.8%与对照组24.3%比较,P<0.05,有统计学意义。结论应用益比奥治疗NSCLC化疗所致贫血疗效好,不良反应少,可减少对输血的需求,同时能提高患者的生活质量。

Objective To observation the therapeutic effect of recombinant human EPO (rbEPO) for the anaemia induced by chemotherapy of non-small cell lung cancer.Methods Fifty-eight non-small cell lung cancer patients with anaemia induced by chemotherapy were readomly divided into treatment group (30 cases) and control group(28 cases).Treatment geoup were performed with 150 U/kg rhEPOthrice per week.Control group were performed with 20 ml Fufang Ejiao Jiang thrice per day.Results Levels of RBC,Hb and HCT of pa- tients in treatment group were obviously in creased than that in control group (P<0.05) The efficient ratio of treatment group (74.8%) was obviously higher than that in control group (24.3%) (P<0.05).Conclusion rhEPO for the treatment of anaemia induced by chemotherapy of NSCLC has advantages including good effects,less side effects and less bood need and can improve the life quality of patients.